14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
IMDX vs CDNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas CDNA carries 32.0/100 (SELL) at $71.92 (46.0x Forward P/E, 1.6% operating margin).
Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. CDNA 32.0/100 SELL), CDNA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (1.6% vs. -1883.2% operating margin) and revenue trajectory (+39.3% vs. +115.0% YoY).
Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Diagnostics & Research value chain with $3.9B market capitalization and 1.6% operating margin.
OpEx & R&D Reinvestment69.4% of Rev ($345M)
90D Engineering Disclosures0 Published
Investor FAQ IMDX vs CDNA Key Questions & Quantitative Answers
As of Nov 19, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas CDNA carries 32.0/100 (SELL) at $71.92 (46.0x Forward P/E, 1.6% operating margin). Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. CDNA 32.0/100 SELL), CDNA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (1.6% vs. -1883.2% operating margin) and revenue trajectory (+39.3% vs. +115.0% YoY). Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMDX leads the Growth & Scale pillar: IMDX posts +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin), compared with CDNA at +39.3% YoY revenue growth and N/A YoY earnings growth on $497M TTM revenue (71.0% gross margin, 1.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IMDX cumulative revenue shifted N/A while CDNA shifted +375.0%. In operating R&D and SG&A reinvestment, IMDX deploys N/A (0 90-day corporate R&D disclosures) versus 69.4% of Rev ($345M) (0 disclosures) for CDNA.
CDNA screens cheaper on headline valuation multiples. IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin), whereas CDNA trades at 46.0x Forward P/E, 31.5x Trailing P/E, N/M PEG, and 7.4x EV/Revenue (12.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMDX (-23603.1% ROE) versus CDNA (33.0% ROE) capital efficiency.
In options market volatility and institutional positioning, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk). By comparison, CDNA carries 64.6% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.27x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.22β · 97% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.